EUVIMEDEUVIMED entdecken
Übersichtsarbeit

The Evolution of Benzodiazepine Allosteric Modulators: Structural Insights From Historical Milestones to Emerging Innovations in Drug Discovery and Development

Hongyu Jiang, Zhipeng Hu, Lixin Yang, Shengcong Chen, Dongbo Tang, Wei Shi, Hai Qian iD

Medicinal Research Reviews · 2026-05 · 46 (3) · 561-584

DOI: 10.1002/med.70026 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Medicinal Research Reviews, online erschienen am 09.11.2025. Verfasst von Hongyu Jiang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center of Drug Discovery, State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing, PR China. Hauptthemen laut MEDLINE: Benzodiazepines, Drug Discovery, Drug Development. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 143 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Benzodiazepine drugs (BZDs) have been central to neuropsychopharmacology since the 1960s, acting as positive allosteric modulators of γ‐aminobutyric acid type A (GABA A ) receptors to enhance inhibitory neurotransmission. Despite their clinical efficacy, long‐term use is limited by tolerance, dependence, and cognitive side effects. This review summarizes the structural evolution of BZD modulators, with a focus on subtype‐selective interactions with GABA A receptor isoforms. Advances in cryo‐electron microscopy and AI‐driven modeling have clarified the architecture and pharmacological roles of distinct receptor subunits, enabling the design of ligands that dissociate therapeutic effects from adverse outcomes. We also highlight the development of nonclassical scaffolds—such as imidazopyridines, triazolopyridazines, and cinnolines—which improve metabolic stability and subtype specificity. In addition, emerging formulation technologies and novel indications, including chronic pain, asthma, and neurodegenerative disorders, broaden the therapeutic scope of BZD‐related compounds. Collectively, these advances underscore a shift toward rational, structure‐based design of next‐generation BZD receptor modulators with improved efficacy, safety, and clinical precision.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BenzodiazepinesDrug DiscoveryDrug DevelopmentHumansAllosteric RegulationReceptors, GABA-AAnimals

Stichwörter der Autor:innen

GABAA receptorsbenzodiazepinesdrug developmentsubtype‐selective agonists

Substanzen

BenzodiazepinesReceptors, GABA-A

Autor:innen und Institutionen

  • Center of Drug Discovery, State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing, PR China.
  • Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing, PR China.

ORCID-Profile: Hai Qian

Zitieren

APA

Jiang, H., Hu, Z., Yang, L., Chen, S., Tang, D., Shi, W., & Qian, H. (2026). The Evolution of Benzodiazepine Allosteric Modulators: Structural Insights From Historical Milestones to Emerging Innovations in Drug Discovery and Development. Medicinal Research Reviews, 46(3), 561-584. https://doi.org/10.1002/med.70026

Vancouver

Jiang H, Hu Z, Yang L, Chen S, Tang D, Shi W, et al. The Evolution of Benzodiazepine Allosteric Modulators: Structural Insights From Historical Milestones to Emerging Innovations in Drug Discovery and Development. Medicinal Research Reviews. 2026;46(3):561-584. doi:10.1002/med.70026

BibTeX
@article{Jiang2026,
  author = {Jiang, Hongyu and Hu, Zhipeng and Yang, Lixin and Chen, Shengcong and Tang, Dongbo and Shi, Wei and Qian, Hai},
  title = {The Evolution of Benzodiazepine Allosteric Modulators: Structural Insights From Historical Milestones to Emerging Innovations in Drug Discovery and Development},
  journal = {Medicinal Research Reviews},
  year = {2026},
  volume = {46},
  number = {3},
  pages = {561--584},
  doi = {10.1002/med.70026}
}
Kostenlos starten →